original ) (raw )Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe
Matthew Dryden
Diagnostic microbiology and infectious disease, 2017
View PDFchevron_right
{"__content__"=>" Activity of Iclaprim against Methicillin-Resistant Nonsusceptible to Daptomycin, Linezolid, or Vancomycin: A Pilot Study.", "i"=>[{"__content__"=>"In Vitro"}, {"__content__"=>"Staphylococcus aureus"}]}
Curtis Gemmell
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2017
View PDFchevron_right
Multicenter, Randomized Study of the Efficacy and Safety of Intravenous Iclaprim in Complicated Skin and Skin Structure Infections
Dainis Krievins
Antimicrobial Agents and Chemotherapy, 2009
View PDFchevron_right
Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety
Matthew Dryden
Future microbiology, 2018
View PDFchevron_right
Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I—results from the SENTRY Antimicrobial Surveillance Program (North America, 1998)
Ronald Jones
Diagnostic Microbiology and Infectious Disease, 2001
View PDFchevron_right
Ceftobiprole: A New Option for Treatment of Skin and Soft-Tissue Infections due to Methicillin-Resistant Staphylococcus aureus
Andreas Widmer
Clinical Infectious Diseases, 2008
View PDFchevron_right
Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options
Tobias Welte
International Journal of Antimicrobial Agents, 2010
View PDFchevron_right
FDA approved antibacterial drugs: 2018-2019
Stefan Andrei
Discoveries, 2019
View PDFchevron_right
Contemporary trends in susceptibilities to older and new antimicrobial agents of clinical Staphylococcus aureus isolates from a Greek University Hospital
Maria Souli
International Journal of Antimicrobial Agents, 2010
View PDFchevron_right
IAP-ICMR call to action to tackle the antimicrobial resistance
vijay yewale
Indian Pediatrics, 2014
View PDFchevron_right
In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals
Marc Struelens
Antimicrobial Agents and Chemotherapy, 2006
View PDFchevron_right
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1
FAISAL AMIN
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017
View PDFchevron_right
ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEETING (68fh) Center for Drug Evaluation and Research, Food and Drug Administration Marriott Washingtonian Center, Gaithersburg, MD
Barry hafkin
View PDFchevron_right
In vitro activity of ceftobiprole against meticillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA
Nasir Husain
International Journal of Antimicrobial Agents, 2010
View PDFchevron_right
What Is the Evidence for Co-trimoxazole, Clindamycin, Doxycycline, and Minocycline in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia?
Tim Lau
Annals of Pharmacotherapy, 2019
View PDFchevron_right
Health Alliance for Prudent Prescribing, Yield and Use of Antimicrobial Drugs in the Treatment of Respiratory Tract Infections (HAPPY AUDIT
Liony González
BMC Family Practice, 2010
View PDFchevron_right
What antibiotics for what pathogens? The sensitivity spectrum of isolated strains in an intensive care unit
Cristian Furau
Science of The Total Environment, 2019
View PDFchevron_right
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim vs. Vancomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens (REVIVE-1)
Rajesh Shukla
Open Forum Infectious Diseases, 2017
View PDFchevron_right
New FDA approved antibacterial drugs: 2015-2017
Stefan Andrei
Discoveries, 2018
View PDFchevron_right
Use of Broad-Spectrum Antimicrobials for the Treatment of Pneumonia in Seriously Ill Patients: Maximizing Clinical Outcomes and Minimizing Selection of Resistant Organisms
Michael Niederman
Clinical Infectious Diseases, 2006
View PDFchevron_right
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Melvin Spigelman
Antimicrobial Agents and Chemotherapy, 2022
View PDFchevron_right
New antibiotics: optimal use in current clinical practice
Drosos Karageorgopoulos
International Journal of Antimicrobial Agents, 2009
View PDFchevron_right
Current Susceptibility Trend of Antibiotics in a Tertiary Care Hospital - Need to Emphasize on Alternate Therapeutic Agents
Manisha Khandait
Microbiology Research Journal International, 2019
View PDFchevron_right
Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections
Matthew Dryden
International journal of antimicrobial agents, 2018
View PDFchevron_right
Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010
Laurent Poirel
Current Opinion in Microbiology, 2007
View PDFchevron_right